The new deal: A potential role for secreted vesicles in innate immunity and tumor progression

Frontiers in Immunology

Volumn 6, Issue FEB, 2015, Pages

  Benito Martin, Alberto ^a   Di Giannatale, Angela ^a   Ceder, Sophia ^b   Peinado, Héctor ^a,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

Exosomes; Innate immunity; Tumor progression; Tumor surveillance

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIPARASITIC AGENT; IFOSFAMIDE; IMATINIB; MIFAMURTIDE;

ADAPTIVE IMMUNITY; BASOPHIL; CELL COMMUNICATION; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CYTOKINE PRODUCTION; EOSINOPHIL; EXOSOME; HOST PARASITE INTERACTION; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOSURVEILLANCE; INNATE IMMUNITY; MACROPHAGE; MAST CELL; NATURAL KILLER CELL; NEUROBLASTOMA; NEUROFIBROMATOSIS; NEUTROPHIL; NONHUMAN; OSTEOSARCOMA; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECRETORY VESICLE; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84926665590     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00066     Document Type: Review

References (138)

1. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell (2006) 127(4):679-95. doi: 10.1016/j.cell.2006.11.001
2. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 19(11):1423-37. doi:10.1038/nm.3394
3. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer (2009) 9(4):274-84. doi:10.1038/nrc2622
4. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 438(7069):820-7. doi:10.1038/nature04186
5. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol (2006) 6(10):715-27. doi:10.1038/nri1936
6. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol (2006) 6(11):836-48. doi:10.1038/nri1961
7. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 14(10):1014-22. doi:10.1038/ni.2703
8. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 29:235-71. doi:10.1146/annurev-immunol-031210-101324
9. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol (2006) 90:1-50. doi:10.1016/S0065-2776(06)90001-7
10. Ghably J, Saleh H, Vyas H, Peiris E, Misra N, Krishnaswamy G. Paul Ehrlich's Mastzellen: a historical perspective of relevant developments in mast cell biology. Methods Mol Biol (2015) 1220:3-10. doi:10.1007/978-1-4939-1568-2_1
11. Burnet FM. Evolution of the immune process in vertebrates. Nature (1968) 218(5140):426-30. doi:10.1038/218426a0
12. Outzen HC, Custer RP. Growth of human normal and neoplastic mammary tissues in the cleared mammary fat pad of the nude mouse. J Natl Cancer Inst (1975) 55(6):1461-6.
13. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 410(6832):1107-11. doi:10.1038/35074122
14. Zitvogel L, Terme M, Borg C, Trinchieri G. Dendritic cell-NK cell cross-talk: regulation and physiopathology. Curr Top Microbiol Immunol (2006) 298:157-74. doi:10.1007/3-540-27743-9_8
15. Coudert JD, Zimmer J, Tomasello E, Cebecauer M, Colonna M, Vivier E, et al. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood (2005) 106(5):1711-7. doi:10.1182/blood-2005-03-0918
16. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 4(1):71-8. doi:10.1038/nrc1256
17. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 315(26):1650-9. doi:10.1056/NEJM198612253152606
18. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 6(1):24-37. doi:10.1038/nrc1782
19. Gould SJ, Raposo G. As we wait: coping with an imperfect nomenclature for extracellular vesicles. J Extracell Vesicles (2013) 2:20389. doi:10.3402/jev.v2i0.20389
20. Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol (2014) 30:255-89. doi:10.1146/annurev-cellbio-101512-122326
21. Trams EG, Lauter CJ, Salem N Jr, Heine U. Exfoliation of membrane ecto-enzymes in the form of micro-vesicles. Biochim Biophys Acta (1981) 645(1):63-70. doi:10.1016/0005-2736(81)90512-5
22. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem (1987) 262(19):9412-20.
23. Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol (2009) 19(2):43-51. doi:10.1016/j.tcb.2008.11.003
24. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol (2002) 2(8):569-79. doi:10.1038/nri855
25. van Niel G, Porto-Carreiro I, Simoes S, Raposo G. Exosomes: a common pathway for a specialized function. J Biochem (2006) 140(1):13-21. doi:10.1093/jb/mvj128
26. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer (2009) 9(4):285-93. doi:10.1038/nrc2621
27. Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol (2011) 21(2):139-46. doi:10.1016/j.semcancer.2011.01.002
28. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med (2012) 18(6):883-91. doi:10.1038/nm.2753
29. Bobrie A, Thery C. Exosomes and communication between tumours and the immune system: are all exosomes equal? Biochem Soc Trans (2013) 41(1):263-7. doi:10.1042/BST20120245
30. Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol (2008) 8(6):478-86. doi:10.1038/nri2327
31. Coussens LM, Werb Z. Inflammation and cancer. Nature (2002) 420(6917):860-7. doi:10.1038/nature01322
32. Nilsson G, Butterfield JH, Nilsson K, Siegbahn A. Stem cell factor is a chemotactic factor for human mast cells. J Immunol (1994) 153(8):3717-23.
33. Zhang W, Stoica G, Tasca SI, Kelly KA, Meininger CJ. Modulation of tumor angiogenesis by stem cell factor. Cancer Res (2000) 60(23):6757-62.
34. Vliagoftis H, Metcalfe DD. Characterization of adhesive interactions between mast cells and laminin isoforms: evidence of a principal role for alpha 6 integrin. Immunology (1997) 92(4):553-60. doi:10.1046/j.1365-2567.1997.00368.x
35. Frossi B, De Carli M, Pucillo C. The mast cell: an antenna of the microenvironment that directs the immune response. J Leukoc Biol (2004) 75(4):579-85. doi:10.1189/jlb.0603275
36. Sorbo J, Jakobsson A, Norrby K. Mast-cell histamine is angiogenic through receptors for histamine1 and histamine2. Int J Exp Pathol (1994) 75(1):43-50.
37. Ribatti D, Vacca A, Ria R, Marzullo A, Nico B, Filotico R, et al. Neovascularisation, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. Eur J Cancer (2003) 39(5):666-74. doi:10.1016/S0959-8049(02)00150-8
38. Raza SL, Cornelius LA. Matrix metalloproteinases: pro-and anti-angiogenic activities. J Investig Dermatol Symp Proc (2000) 5(1):47-54. doi:10.1046/j.1087-0024.2000.00004.x
39. Skokos D, Botros HG, Demeure C, Morin J, Peronet R, Birkenmeier G, et al. Mast cell-derived exosomes induce phenotypic and functional maturation of dendritic cells and elicit specific immune responses in vivo. J Immunol (2003) 170(6):3037-45. doi:10.4049/jimmunol.170.6.3037
40. Skokos D, Le Panse S, Villa I, Rousselle JC, Peronet R, David B, et al. Mast cell-dependent B and T lymphocyte activation is mediated by the secretion of immunologically active exosomes. J Immunol (2001) 166(2):868-76. doi:10.4049/jimmunol.166.2.868
41. Ekstrom K, Valadi H, Sjostrand M, Malmhall C, Bossios A, Eldh M, et al. Characterization of mRNA and microRNA in human mast cell-derived exosomes and their transfer to other mast cells and blood CD34 progenitor cells. J Extracell Vesicles (2012) 1:18389. doi:10.3402/jev.v1i0.18389
42. Vincent-Schneider H, Stumptner-Cuvelette P, Lankar D, Pain S, Raposo G, Benaroch P, et al. Exosomes bearing HLA-DR1 molecules need dendritic cells to efficiently stimulate specific T cells. Int Immunol (2002) 14(7):713-22. doi:10.1093/intimm/dxf048
43. Skokos D, Goubran-Botros H, Roa M, Mecheri S. Immunoregulatory properties of mast cell-derived exosomes. Mol Immunol (2002) 38(16-18):1359-62. doi:10.1016/S0161-5890(02)00088-3
44. Carroll-Portillo A, Surviladze Z, Cambi A, Lidke DS, Wilson BS. Mast cell synapses and exosomes: membrane contacts for information exchange. Front Immunol (2012) 3:46. doi:10.3389/fimmu.2012.00046
45. Tkaczyk C, Frandji P, Botros HG, Poncet P, Lapeyre J, Peronet R, et al. Mouse bone marrow-derived mast cells and mast cell lines constitutively produce B cell growth and differentiation activities. J Immunol (1996) 157(4):1720-8.
46. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol (2007) 9(6):654-9. doi:10.1038/ncb1596
47. Lötvall J, Valadi H. Cell to cell signalling via exosomes through esRNA. Cell Adh Migr (2007) 1(3):156-8. doi:10.4161/cam.1.3.5114
48. Fukushima H, Ohsawa M, Ikura Y, Naruko T, Sugama Y, Suekane T, et al. Mast cells in diffuse large B-cell lymphoma; their role in fibrosis. Histopathology (2006) 49(5):498-505. doi:10.1111/j.1365-2559.2006.02534.x
49. Sharma VK, Agrawal A, Pratap VK, Nagar AM, Mehrotra ML. Mast cell reactivity in lymphoma: a preliminary communication. Indian J Cancer (1992) 29(2):61-5.
50. Rojas IG, Spencer ML, Martinez A, Maurelia MA, Rudolph MI. Characterization of mast cell subpopulations in lip cancer. J Oral Pathol Med (2005) 34(5):268-73. doi:10.1111/j.1600-0714.2004.00297.x
51. Groot Kormelink T, Abudukelimu A, Redegeld FA. Mast cells as target in cancer therapy. Curr Pharm Des (2009) 15(16):1868-78. doi:10.2174/138161209788453284
52. Nonomura N, Takayama H, Nishimura K, Oka D, Nakai Y, Shiba M, et al. Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer. Br J Cancer (2007) 97(7):952-6. doi:10.1038/sj.bjc.6603962
53. Rajput AB, Turbin DA, Cheang MC, Voduc DK, Leung S, Gelmon KA, et al. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res Treat (2008) 107(2):249-57. doi:10.1007/s10549-007-9546-3
54. Welsh TJ, Green RH, Richardson D, Waller DA, O'Byrne KJ, Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol (2005) 23(35):8959-67. doi:10.1200/JCO.2005.01.4910
55. Ribatti D, Vacca A, Marzullo A, Nico B, Ria R, Roncali L, et al. Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Int J Cancer (2000) 85(2):171-5. doi:10.1002/(SICI)1097-0215(20000115)85:2<171::AID-IJC4>3.0.CO;2-W
56. Xiao H, Lasser C, Shelke G, Wang J, Radinger M, Lunavat T, et al. Mast cell exosomes promote lung adenocarcinoma cell proliferation inverted question mark role of KIT-stem cell factor signaling. Cell Commun Signal (2014) 12(1):64. doi:10.1186/PREACCEPT-1817458803126023
57. Mayadas TN, Cullere X, Lowell CA. The multifaceted functions of neutrophils. Annu Rev Pathol (2014) 9:181-218. doi:10.1146/annurev-pathol-020712-164023
58. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell (2009) 16(3):183-94. doi:10.1016/j.ccr.2009.06.017
59. Kowanetz M, Wu X, Lee J, Tan M, Hagenbeek T, Qu X, et al. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A (2010) 107(50):21248-55. doi:10.1073/pnas.1015855107
60. Yan HH, Pickup M, Pang Y, Gorska AE, Li Z, Chytil A, et al. Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res (2010) 70(15):6139-49. doi:10.1158/0008-5472.CAN-10-0706
61. Bobrie A, Krumeich S, Reyal F, Recchi C, Moita LF, Seabra MC, et al. Rab27a supports exosome-dependent and-independent mechanisms that modify the tumor microenvironment and can promote tumor progression. Cancer Res (2012) 72(19):4920-30. doi:10.1158/0008-5472.CAN-12-0925
62. Esser J, Gehrmann U, D'Alexandri FL, Hidalgo-Estevez AM, Wheelock CE, Scheynius A, et al. Exosomes from human macrophages and dendritic cells contain enzymes for leukotriene biosynthesis and promote granulocyte migration. J Allergy Clin Immunol (2010) 126(5):1032-40, 1040.e1-4. doi:10.1016/j.jaci.2010.06.039
63. Afonso PV, Janka-Junttila M, Lee YJ, McCann CP, Oliver CM, Aamer KA, et al. LTB4 is a signal-relay molecule during neutrophil chemotaxis. Dev Cell (2012) 22(5):1079-91. doi:10.1016/j.devcel.2012.02.003
64. Houghton AM. The paradox of tumor-associated neutrophils: fueling tumor growth with cytotoxic substances. Cell Cycle (2010) 9(9):1732-7. doi:10.4161/cc.9.9.11297
65. Mittendorf EA, Alatrash G, Qiao N, Wu Y, Sukhumalchandra P, St John LS, et al. Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune response. Cancer Res (2012) 72(13):3153-62. doi:10.1158/0008-5472.CAN-11-4135
66. Timar CI, Lorincz AM, Csepanyi-Komi R, Valyi-Nagy A, Nagy G, Buzas EI, et al. Antibacterial effect of microvesicles released from human neutrophilic granulocytes. Blood (2013) 121(3):510-8. doi:10.1182/blood-2012-05-431114
67. Hess C, Sadallah S, Hefti A, Landmann R, Schifferli JA. Ectosomes released by human neutrophils are specialized functional units. J Immunol (1999) 163(8):4564-73.
68. Gasser O, Hess C, Miot S, Deon C, Sanchez JC, Schifferli JA. Characterisation and properties of ectosomes released by human polymorphonuclear neutrophils. Exp Cell Res (2003) 285(2):243-57. doi:10.1016/S0014-4827(03)00055-7
69. Eken C, Sadallah S, Martin PJ, Treves S, Schifferli JA. Ectosomes of polymorphonuclear neutrophils activate multiple signaling pathways in macrophages. Immunobiology (2013) 218(3):382-92. doi:10.1016/j.imbio.2012.05.021
70. Dalli J, Montero-Melendez T, Norling LV, Yin X, Hinds C, Haskard D, et al. Heterogeneity in neutrophil microparticles reveals distinct proteome and functional properties. Mol Cell Proteomics (2013) 12(8):2205-19. doi:10.1074/mcp.M113.028589
71. Marton A, Vizler C, Kusz E, Temesfoi V, Szathmary Z, Nagy K, et al. Melanoma cell-derived exosomes alter macrophage and dendritic cell functions in vitro. Immunol Lett (2012) 148(1):34-8. doi:10.1016/j.imlet.2012.07.006
72. Soki FN, Koh AJ, Jones JD, Kim YW, Dai J, Keller ET, et al. Polarization of prostate cancer-associated macrophages is induced by milk fat globule-EGF factor 8 (MFG-E8)-mediated efferocytosis. J Biol Chem (2014) 289(35):24560-72. doi:10.1074/jbc.M114.571620
73. Ismail N, Wang Y, Dakhlallah D, Moldovan L, Agarwal K, Batte K, et al. Macrophage microvesicles induce macrophage differentiation and miR-223 transfer. Blood (2013) 121(6):984-95. doi:10.1182/blood-2011-08-374793
74. Bhatnagar S, Shinagawa K, Castellino FJ, Schorey JS. Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo. Blood (2007) 110(9):3234-44. doi:10.1182/blood-2007-03-079152
75. Kim J, Morley S, Le M, Bedoret D, Umetsu DT, Di Vizio D, et al. Enhanced shedding of extracellular vesicles from amoeboid prostate cancer cells: potential effects on the tumor microenvironment. Cancer Biol Ther (2014) 15(4):409-18. doi:10.4161/cbt.27627
76. Madrigal-Matute J, Lindholt JS, Fernandez-Garcia CE, Benito-Martin A, Burillo E, Zalba G, et al. Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis. J Am Heart Assoc (2014) 3(4):e000785. doi:10.1161/JAHA.114.000785
77. Chow A, Zhou W, Liu L, Fong MY, Champer J, Van Haute D, et al. Macrophage immunomodulation by breast cancer-derived exosomes requires toll-like receptor 2-mediated activation of NF-kappaB. Sci Rep (2014) 4:5750. doi:10.1038/srep05750
78. Lee HD, Kim YH, Kim DS. Exosomes derived from human macrophages suppress endothelial cell migration by controlling integrin trafficking. Eur J Immunol (2014) 44(4):1156-69. doi:10.1002/eji.201343660
79. Yang M, Chen J, Su F, Yu B, Lin L, Liu Y, et al. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol Cancer (2011) 10:117. doi:10.1186/1476-4598-10-117
80. Kita H. Eosinophils: multifaceted biological properties and roles in health and disease. Immunol Rev (2011) 242(1):161-77. doi:10.1111/j.1600-065X.2011.01026.x
81. Fernandez-Acenero MJ, Galindo-Gallego M, Sanz J, Aljama A. Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer (2000) 88(7):1544-8. doi:10.1002/(SICI)1097-0142(20000401)88:7<1544::AID-CNCR7>3.0.CO;2-S
82. Munitz A, Levi-Schaffer F. Eosinophils: 'new' roles for 'old' cells. Allergy (2004) 59(3):268-75. doi:10.1111/j.1398-9995.2003.00442.x
83. Pinto A, Aldinucci D, Gloghini A, Zagonel V, Degan M, Improta S, et al. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood (1996) 88(9):3299-305.
84. Lotfi R, Lee JJ, Lotze MT. Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J Immunother (2007) 30(1):16-28. doi:10.1097/01.cji.0000211324.53396.f6
85. Behzad AR, Walker DC, Abraham T, McDonough J, Mahmudi-Azer S, Chu F, et al. Localization of DNA and RNA in eosinophil secretory granules. Int Arch Allergy Immunol (2010) 152(1):12-27. doi:10.1159/000260079
86. Muniz VS, Weller PF, Neves JS. Eosinophil crystalloid granules: structure, function, and beyond. J Leukoc Biol (2012) 92(2):281-8. doi:10.1189/jlb.0212067
87. Neves JS, Perez SA, Spencer LA, Melo RC, Weller PF. Subcellular fractionation of human eosinophils: isolation of functional specific granules on isoosmotic density gradients. J Immunol Methods (2009) 344(1):64-72. doi:10.1016/j.jim.2009.03.006
88. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol (2008) 9(5):503-10. doi:10.1038/ni1582
89. Lugini L, Cecchetti S, Huber V, Luciani F, Macchia G, Spadaro F, et al. Immune surveillance properties of human NK cell-derived exosomes. J Immunol (2012) 189(6):2833-42. doi:10.4049/jimmunol.1101988
90. Villa-Morales M, Fernandez-Piqueras J. Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 16(1):85-101. doi:10.1517/14728222.2011.628937
91. Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med (2014) 20(6):607-15. doi:10.1038/nm.3541
92. Brennan AJ, Chia J, Trapani JA, Voskoboinik I. Perforin deficiency and susceptibility to cancer. Cell Death Differ (2010) 17(4):607-15. doi:10.1038/cdd.2009.212
93. Fais S. NK cell-released exosomes: natural nanobullets against tumors. Oncoimmunology (2013) 2(1):e22337. doi:10.4161/onci.22337
94. Liu C, Yu S, Zinn K, Wang J, Zhang L, Jia Y, et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol (2006) 176(3):1375-85. doi:10.4049/jimmunol.176.3.1375
95. Gastpar R, Gehrmann M, Bausero MA, Asea A, Gross C, Schroeder JA, et al. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res (2005) 65(12):5238-47. doi:10.1158/0008-5472.CAN-04-3804
96. Clayton A, Tabi Z. Exosomes and the MICA-NKG2D system in cancer. Blood Cells Mol Dis (2005) 34(3):206-13. doi:10.1016/j.bcmd.2005.03.003
97. Baragano Raneros A, Suarez-Alvarez B, Lopez-Larrea C. Secretory pathways generating immunosuppressive NKG2D ligands: new targets for therapeutic intervention. Oncoimmunology (2014) 3:e28497. doi:10.4161/onci.28497
98. Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z. Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol (2008) 180(11):7249-58. doi:10.4049/jimmunol.180.11.7249
99. Paolino M, Choidas A, Wallner S, Pranjic B, Uribesalgo I, Loeser S, et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature (2014) 507(7493):508-12. doi:10.1038/nature12998
100. Tsai IJ, Zarowiecki M, Holroyd N, Garciarrubio A, Sanchez-Flores A, Brooks KL, et al. The genomes of four tapeworm species reveal adaptations to parasitism. Nature (2013) 496(7443):57-63. doi:10.1038/nature12031
101. Doudican N, Rodriguez A, Osman I, Orlow SJ. Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mol Cancer Res (2008) 6(8):1308-15. doi:10.1158/1541-7786.MCR-07-2159
102. Hooft van Huijsduijnen R, Guy RK, Chibale K, Haynes RK, Peitz I, Kelter G, et al. Anticancer properties of distinct antimalarial drug classes. PLoS One (2013) 8(12):e82962. doi:10.1371/journal.pone.0082962
103. Benamrouz S, Conseil V, Creusy C, Calderon E, Dei-Cas E, Certad G. Parasites and malignancies, a review, with emphasis on digestive cancer induced by Cryptosporidium parvum (Alveolata: Apicomplexa). Parasite (2012) 19(2):101-15. doi:10.1051/parasite/2012192101
104. Mandong BM, Ngbea JA, Raymond V. Role of parasites in cancer. Niger J Med (2013) 22(2):89-92.
105. Marcilla A, Martin-Jaular L, Trelis M, de Menezes-Neto A, Osuna A, Bernal D, et al. Extracellular vesicles in parasitic diseases. J Extracell Vesicles (2014) 3:25040. doi:10.3402/jev.v3.25040
106. Silverman JM, Clos J, Horakova E, Wang AY, Wiesgigl M, Kelly I, et al. Leishmania exosomes modulate innate and adaptive immune responses through effects on monocytes and dendritic cells. J Immunol (2010) 185(9):5011-22. doi:10.4049/jimmunol.1000541
107. Divangahi M, Desjardins D, Nunes-Alves C, Remold HG, Behar SM. Eicosanoid pathways regulate adaptive immunity to Mycobacterium tuberculosis. Nat Immunol (2010) 11(8):751-8. doi:10.1038/ni.1904
108. Jiang L, Mu J, Zhang Q, Ni T, Srinivasan P, Rayavara K, et al. PfSETvs methylation of histone H3K36 represses virulence genes in Plasmodium falciparum. Nature (2013) 499(7457):223-7. doi:10.1038/nature12361
109. Staser K, Yang FC, Clapp DW. Mast cells and the neurofibroma microenvironment. Blood (2010) 116(2):157-64. doi:10.1182/blood-2009-09-242875
110. Riccardi VM. Neurofibromatosis: past, present, and future. N Engl J Med (1991) 324(18):1283-5. doi:10.1056/NEJM199105023241812
111. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science (2002) 296(5569):920-2. doi:10.1126/science.1068452
112. Yang FC, Ingram DA, Chen S, Hingtgen CM, Ratner N, Monk KR, et al. Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1± mast cells. J Clin Invest (2003) 112(12):1851-61. doi:10.1172/JCI19195
113. Chen S, Burgin S, McDaniel A, Li X, Yuan J, Chen M, et al. Nf1-/-Schwann cell-conditioned medium modulates mast cell degranulation by c-Kit-mediated hyperactivation of phosphatidylinositol 3-kinase. Am J Pathol (2010) 177(6):3125-32. doi:10.2353/ajpath.2010.100369
114. Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol (1998) 160(3):1224-32.
115. Taraboletti G, D'Ascenzo S, Giusti I, Marchetti D, Borsotti P, Millimaggi D, et al. Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. Neoplasia (2006) 8(2):96-103. doi:10.1593/neo.05583
116. Lasater EA, Li F, Bessler WK, Estes ML, Vemula S, Hingtgen CM, et al. Genetic and cellular evidence of vascular inflammation in neurofibromin-deficient mice and humans. J Clin Invest (2010) 120(3):859-70. doi:10.1172/JCI41443
117. Wu M, Wallace MR, Muir D. Nf1 haploinsufficiency augments angiogenesis. Oncogene (2006) 25(16):2297-303. doi:10.1038/sj.onc.1209264
118. Robertson KA, Nalepa G, Yang FC, Bowers DC, Ho CY, Hutchins GD, et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol (2012) 13(12):1218-24. doi:10.1016/S1470-2045(12)70414-X
119. Riccardi VM. A controlled multiphase trial of ketotifen to minimize neurofibroma-associated pain and itching. Arch Dermatol (1993) 129(5):577-81. doi:10.1001/archderm.129.5.577
120. Prada CE, Jousma E, Rizvi TA, Wu J, Dunn RS, Mayes DA, et al. Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neuropathol (2013) 125(1):159-68. doi:10.1007/s00401-012-1056-7
121. Kager L, Potschger U, Bielack S. Review of mifamurtide in the treatment of patients with osteosarcoma. Ther Clin Risk Manag (2010) 6:279-86. doi:10.2147/TCRM.S5688
122. Hunsberger S, Freidlin B, Smith MA. Complexities in interpretation of osteosarcoma clinical trial results. J Clin Oncol (2008) 26(18):3103-4. doi:10.1200/JCO.2008.17.3484
123. Kirman I, Belizon A, Balik E, Feingold D, Arnell T, Horst P, et al. Perioperative sargramostim (recombinant human GM-CSF) induces an increase in the level of soluble VEGFR1 in colon cancer patients undergoing minimally invasive surgery. Eur J Surg Oncol (2007) 33(10):1169-76. doi:10.1016/j.ejso.2007.03.014
124. Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg (2013) 258(6):879-86. doi:10.1097/SLA.0b013e318292919e
125. Bacci G, Briccoli A, Rocca M, Ferrari S, Donati D, Longhi A, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol (2003) 14(7):1126-34. doi:10.1093/annonc/mdg286
126. Pahl JH, Kwappenberg KM, Varypataki EM, Santos SJ, Kuijjer ML, Mohamed S, et al. Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-gamma. J Exp Clin Cancer Res (2014) 33:27. doi:10.1186/1756-9966-33-27
127. Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today (1990) 11(7):237-44. doi:10.1016/0167-5699(90)90097-S
128. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res (2002) 62(21):6178-86.
129. Corrias MV, Occhino M, Croce M, De Ambrosis A, Pistillo MP, Bocca P, et al. Lack of HLA-class I antigens in human neuroblastoma cells: analysis of its relationship to TAP and tapasin expression. Tissue Antigens (2001) 57(2):110-7. doi:10.1034/j.1399-0039.2001.057002110.x
130. Raffaghello L, Prigione I, Bocca P, Morandi F, Camoriano M, Gambini C, et al. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene (2005) 24(29):4634-44. doi:10.1038/sj.onc.1208594
131. Chitadze G, Lettau M, Bhat J, Wesch D, Steinle A, Furst D, et al. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17. Int J Cancer (2013) 133(7):1557-66. doi:10.1002/ijc.28174
132. Cassatella MA. On the production of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2L) by human neutrophils. J Leukoc Biol (2006) 79(6):1140-9. doi:10.1189/jlb.1005558
133. Marimpietri D, Petretto A, Raffaghello L, Pezzolo A, Gagliani C, Tacchetti C, et al. Proteome profiling of neuroblastoma-derived exosomes reveal the expression of proteins potentially involved in tumor progression. PLoS One (2013) 8(9):e75054. doi:10.1371/journal.pone.0075054
134. Whiteside TL. Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans (2013) 41(1):245-51. doi:10.1042/BST20120265
135. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol (2010) 28(6):955-9. doi:10.1200/JCO.2009.24.4590
136. Castano-Milla C, Chaparro M, Gisbert JP. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther (2014) 39(7):645-59. doi:10.1111/apt.12651
137. Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One (2014) 9(4):e92921. doi:10.1371/journal.pone.0092921
138. Karlsson M, Lundin S, Dahlgren U, Kahu H, Pettersson I, Telemo E. "Tolerosomes" are produced by intestinal epithelial cells. Eur J Immunol (2001) 31(10):2892-900. doi:10.1002/1521-4141(2001010)31:10<2892::AID-IMMU2892>3.0.CO;2-I